Browse By: Country ι Category ι Tag
Home  »  Head and Neck Cancer

Head and Neck Cancer Market Research Reports

More

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation
Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is rising. The term head and neck cancer (HNC) comprises a number of malignancies that usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck. These cancers develop inside the mouth, nose and throat. The annual incidence of head and neck cancers worldwide is more than 550,000 cases, with around 300,000 related deaths. Peak incidence occurs between the ages of 55 and 64. 
Published Date: Mar 2017
Published By: GBI Research

Price: $6995
Global Head and Neck Cancer Partnering 2010 to 2017
• Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation o
Published Date: Feb 2017
Published By: Current Partnering

Price: $1495
Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2017
DelveInsight’s, “ Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Recurrent Head And Neck Cancer Squamous Cell Carcinoma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Recurrent Head A
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Head and neck cancer (HNC) - Market Insights, Epidemiology and Market Forecast-2023
Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Head and neck cancer market. • Identifying patient populations in the global “Head and neck cancer market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Head and neck cancer therapeutics in each of the markets covered. • To understand the future market competition in the global Head and neck cancer therapeutics market and Insightful review of the key market drivers and barriers. Scope • Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options. • Marketed information
Published Date: Jan 2017
Published By: DelveInsight

Price: $4950
Head And Neck Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Head And Neck Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Head And Neck Cancer Report is to understand the market and pipeline status of the drugs around the Head And Neck Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Head And Neck Cancer. W
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Head and neck cancer (HNC)- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Head and neck cancer (HNC) subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Head and neck cancer (HNC) market. • Identifying prevalent patient populations as well as risk fa
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2017
DelveInsight’s, “ Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Head And Neck Cancer Squamous Cell Carcinoma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Head And Neck Cancer Squamous Cell C
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Head and neck cancer (HNC) - Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Head and neck cancer (HNC) subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Head and neck cancer (HNC) market. • Identifying prevalent patient populations as well as risk fa
Published Date: Nov 2016
Published By: DelveInsight

Price: $2750
Head And Neck Cancer - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer – Pipeline Review, H2 2016, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape. Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer – Pipel
Published Date: Oct 2016
Published By: Global Markets Direct

Price: $2500
Head And Neck Cancer Global Clinical Trials Review, H1, 2016
Summary GlobalData's clinical trial report, “Head And Neck Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Head And Neck Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Head And Neck Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 8
Published Date: May 2016
Published By: GlobalData

Price: $2500
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016’, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and feature
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Global Head and Neck Cancer Partnering 2010 to 2016
• Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation o
Published Date: May 2016
Published By: Current Partnering

Price: $1495
Head and neck Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Head And Neck Cancer - Pipeline Review, H1 2016’, provides an overview of the Head And Neck Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational d
Published Date: Apr 2016
Published By: Global Markets Direct

Price: $2500
Head and neck cancer (HNC) - Market Insights, Epidemiology and Market Forecast-2020
Note*: This report requires 5-10 business days to complete. DelveInsight’s Head and neck cancer (HNC) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the disease and global market trends of the %Indication"% for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Head and neck cancer (HNC) forecasted market share for ten years to 2020 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Head and neck cancer (HNC) till 2020. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and drivin
Published Date: Apr 2016
Published By: DelveInsight

Price: $4950
EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024
?Head and neck cancers (HNCs) are a heterogeneous group, consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth; the salivary glands; the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx; the nose, sinuses, and related structures; the larynx; and the thyroid.
Published Date: Feb 2016
Published By: GlobalData

Price: $3995
Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2016
DelveInsight’s, “ Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Head And Neck Cancer Squamous Cell Carcinoma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Head And Neck Cancer Squamous Cell C
Published Date: Jan 2016
Published By: DelveInsight

Price: $1250
Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2016
DelveInsight’s, “ Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Recurrent Head And Neck Cancer Squamous Cell Carcinoma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Recurrent Head A
Published Date: Jan 2016
Published By: DelveInsight

Price: $1250
Head And Neck Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
DelveInsight’s Report, “Head And Neck Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Head And Neck Cancer Report is to understand the market and pipeline status of the drugs around the Head And Neck Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Head And Neck Cancer. W
Published Date: Jan 2016
Published By: DelveInsight

Price: $2000
Head And Neck Cancer - Pipeline Review, H2 2015
Summary Global Markets Direct’s, ‘Head And Neck Cancer - Pipeline Review, H2 2015’, provides an overview of the Head And Neck Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications
Published Date: Dec 2015
Published By: Global Markets Direct

Price: $2500
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015
Summary Global Markets Direct’s, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015’, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Globa
Published Date: Oct 2015
Published By: Global Markets Direct

Price: $2000

Back To Top